英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Shepherding查看　Shepherding　在百度字典中的解释百度英翻中〔查看〕
Shepherding查看　Shepherding　在Google字典中的解释Google英翻中〔查看〕
Shepherding查看　Shepherding　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Managing Ulcerative Colitis With Velsipity - WebMD
    Velsipity (Vel-sip-itee) was approved in 2023 to treat moderate to severe ulcerative colitis in adults How Does It Work? Ulcerative colitis (UC) is a disease that causes inflammation in your
  • VELSIPITY® (etrasimod) for Adults with Moderate to Severe UC | Risk Info
    If other treatments like 5-ASAs † or steroids aren’t working well enough* for you, ask your doctor about oral VELSIPITY †5-ASAs are 5-aminosalicylic acid derivatives *In VELSIPITY studies, people with moderately to severely active ulcerative colitis had an inadequate response, loss of response, or intolerance to one or more of the following treatment options: oral aminosalicylates
  • Once-Daily Pill for UC Treatment | VELSIPITY™ (etrasimod) | Risk Info
    Indication VELSIPITY ® (etrasimod) is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults Important Safety Information Contraindications Patients in the last 6 months who experienced myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring
  • U. S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to . . .
    Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials Pfizer Inc (NYSE: PFE) announced today that the U S Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC)
  • Velsipity: Uses, Dosage, Side Effects, Warnings - Drugs. com
    Velsipity tablets have a rapid onset action with ulcerative colitis (UC) symptoms improving and symptomatic remission starting as early as week 2 in some patients Velsipity is an S1P receptor modulator (selective sphingosine-1-phosphate) that helps control inflammation in the large intestine
  • Pfizer Has a New Oral Pill for Ulcerative Colitis - Verywell Health
    The FDA approved Velsipity (etrasimod), a drug by Pfizer to treat ulcerative colitis The daily oral pill can reduce inflammation in the gut and help patients reach remission The approval adds another treatment option for patients who respond poorly to, and prefer not to take, an injectable biologic drug or steroid
  • Etrasimod for moderate to severe ulcerative colitis - PMC
    Background: Ulcerative colitis is an immune-mediated inflammatory bowel disease It involves chronic, relapsing intestinal manifestations, such as diarrhoea, urgency or tenesmus, and blood in the stools, but can also be associated with extra-intestinal manifestations (e g arthropathy) 1 The mainstays of induction treatment are 5-aminosalicylates (5-ASAs) and corticosteroids
  • VELSIPITY™ Receives Health Canada Approval for Adults with . . . - Pfizer
    A once-daily oral treatment, VELSIPITY is for adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or an advanced treatment Ulcerative Colitis (UC) is the most common form of inflammatory bowel disease (IBD)
  • NICE recommends etrasimod (Velsipity) for Ulcerative Colitis
    The brand name for etrasimod is Velsipity Who can have etrasimod? NICE has recommended etrasimod as a treatment option for moderately to severely active Ulcerative Colitis in people who: Are aged 16 and over; Have had to stop conventional or biological treatments because of side effects; Have found that other treatments don’t work for them
  • Clinical Overview: Etrasimod for Ulcerative Colitis - Pharmacy Times
    In October 2023, the FDA granted approval for etrasimod under the brand name Velsipty (Pfizer), intended for the treatment of adults suffering from moderately to severely active ulcerative colitis (UC) 1 This approval was grounded in positive outcomes stemming from Pfizer's ELEVATE UC phase 3 registrational program, which encompassed the ELEVATE UC 52 and ELEVATE UC 12 clinical trials





中文字典-英文字典  2005-2009